E-islet 01 allogeneic human regenerative islets
EndoCell Therapeutics, Inc.
Early-stage; watch this space.
EndoCell Therapeutics' allogeneic human E-islet product is a stem-cell-derived islet-replacement approach delivered through the hepatic portal vein. A Phase 1/2a trial in adults with long-standing T1D, impaired hypoglycemia awareness, and severe hypoglycemia is recruiting in China; early human stem-cell-derived islet experience has been published, but the registered E-islet 01 trial has no posted efficacy results yet.
The scorecard
Published early human experience with autologous/allogeneic stem-cell-derived islets exists, and the E-islet 01 trial includes insulin-independence-adjacent endpoints, but this specific registered product has no posted efficacy results yet.[2]
The active trial follows participants for up to 5 years, but durable graft function for E-islet 01 is not yet reported.[1]
The registry describes allogeneic cells infused into the portal vein and does not establish an immunosuppression-free protection strategy in the public record, so immune-drug burden remains unclear.[1]
Portal-vein infusion is less invasive than a major implant operation but still carries the procedural burden and non-retrievability issues of intrahepatic islet transplantation.[1]
The current trial targets a narrow high-risk group: adults 18-75 with T1D, impaired hypoglycemia awareness, and severe hypoglycemia at a single listed Shanghai site.[1]
Recruiting Phase 1/2a trial with 21 planned participants; important but still early human development.[1]
The full picture
What it is
E-islet 01 is EndoCell Therapeutics' allogeneic human islet-replacement product for people with established type 1 diabetes who have impaired awareness of hypoglycemia and severe hypoglycemia.1 The public registry describes it as Allogeneic Human E-islet (E-islet 01), infused into the hepatic portal vein.1 That places it in the same broad family as donor-islet and Vertex zimislecel approaches: replacing missing insulin-producing cells rather than asking an algorithm to dose insulin around them.
Clinical status
The registered study, NCT07126873, is a Phase 1/2a, open-label, sequential trial at Shanghai Changzheng Hospital.1 It plans 21 adults aged 18-75, with follow-up to 5 years.1 The primary outcomes include safety/tolerability and the proportion of participants free of severe hypoglycemia with HbA1c improvement at 1 year after infusion.1
What is known so far
The strongest published signal near this program is a 2026 Lancet Diabetes & Endocrinology report of autologous and allogeneic stem-cell-derived islet therapy in three people with T1D and complete loss of endogenous beta-cell function before transplant.2 That supports the broader E-islet platform as clinically plausible, but it does not mean the registered E-islet 01 trial has proved efficacy. ClinicalTrials.gov lists the E-islet 01 study as recruiting and does not post trial results.1
Key caveats
The registry does not establish an immunosuppression-free protection strategy, and the product is infused into the portal vein rather than placed in a retrievable device.1 Until public results clarify immune regimen, C-peptide durability, insulin-use reduction, and safety, this belongs as an early pipeline cell-replacement record, not a proven cure.
References
-
EndoCell Therapeutics, Inc. A Safety, Tolerability, and Efficacy Study of E-islet 01 in Participants With Type 1 Diabetes. ClinicalTrials.gov NCT07126873 (last updated 2025). https://clinicaltrials.gov/study/NCT07126873 ↩ ↩2 ↩3 ↩4 ↩5 ↩6 ↩7
-
Shi Y, Feng Y, Li T, et al. Autologous and allogeneic stem cell-derived islet therapy in three recipients with type 1 diabetes and complete loss of endogenous pancreatic beta-cell function pretransplant. Lancet Diabetes Endocrinol (2026). https://doi.org/10.1016/S2213-8587%2825%2900423-1 ↩
Coming soon
ETA · Recruiting Phase 1/2a; study completion estimated 2029, with no approval timing yet
- →First registered E-islet 01 safety, C-peptide, glucose, and insulin-use readouts · Trial follow-up runs through 2029
Sources
- [1]A Safety, Tolerability, and Efficacy Study of E-islet 01 in Participants With Type 1 Diabetes · registry · 2025-08-17
- [2]Autologous and allogeneic stem cell-derived islet therapy in three recipients with type 1 diabetes and complete loss of endogenous pancreatic beta-cell function pretransplant · peer-reviewed · 2026-02-26